Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12546MR)

This product GTTS-WQ12546MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12546MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8924MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ6034MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ1424MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ3231MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ7966MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ11680MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ10620MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ4212MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW